文献速递MDS 与骨髓增殖性肿瘤

他汀类药物增强聚乙二醇干扰素α2对费城染色体阴性慢性骨髓增殖性肿瘤的疗效

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms.
PubMed 文献 · Blood Adv · 2025-01-01

这项回顾性队列研究纳入129例费城染色体阴性骨髓增殖性肿瘤患者,其中53例自诊断起使用他汀。他汀使用者达到完全血液学缓解显著更快(中位8 vs 18个月;HR 2.1;95%CI 1.4-3.1;P=.0003),在聚乙二醇干扰素α2治疗者中完全血液学缓解率为97% vs 83%(HR 2.5;95%CI 1.5-3.9;P=.0004),且他汀使用与部分分子学缓解显著相关(HR 2.6;95%CI 1.1-6.0;P=.029)。

要点

  • 他汀使用者完全血液学缓解中位时间8个月 vs 非使用者18个月(HR 2.1;95%CI 1.4-3.1;P=.0003)。
  • 聚乙二醇干扰素α2治疗者中,他汀使用者完全血液学缓解率97% vs 非使用者83%(HR 2.5;95%CI 1.5-3.9;P=.0004)。
  • 他汀使用与干扰素α2治疗者部分分子学缓解显著相关(HR 2.6;95%CI 1.1-6.0;P=.029)。

核心结论

  • 他汀可能增强聚乙二醇干扰素α2对骨髓增殖性肿瘤患者的疗效,而他汀对羟基脲治疗患者的获益仍不明确。
  • 需要前瞻性研究进一步探索他汀在骨髓增殖性肿瘤中的治疗潜力。

研究设计与样本

  • 回顾性队列研究,共纳入129例费城染色体阴性骨髓增殖性肿瘤患者,其中53例自诊断起接受他汀治疗。

主要发现

  • 他汀使用者达到完全血液学缓解显著快于非使用者:中位时间8 vs 18个月;HR 2.1;95%CI 1.4-3.1;P=.0003。
  • 聚乙二醇干扰素α2治疗患者中,他汀使用者完全血液学缓解率为97% vs 非使用者83%;HR 2.5;95%CI 1.5-3.9;P=.0004,且更高比例的他汀使用者在整个随访期间维持完全血液学缓解。
  • 接受干扰素治疗的他汀使用者平均干扰素α2剂量显著更低。
  • 观察到剂量-反应关系:他汀强度越高,完全血液学缓解增加越多。
  • 他汀使用与聚乙二醇干扰素α2治疗患者达到部分分子学缓解显著相关:HR 2.6;95%CI 1.1-6.0;P=.029;在羟基脲治疗患者中未观察到显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic inflammation may be a key driving force in the development and progression of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). Statins, commonly used to lower cholesterol, also possess antiproliferative, proapoptotic, and anti-inflammatory properties that may be beneficial in the treatment of patients with MPN. This retrospective cohort study investigated whether statin use, in addition to standard cytoreductive therapy, shortens the time required to achieve hematological and molecular responses, while allowing for lower cytoreductive drug dosages. A total of 129 patients were included, with 53 receiving statins from diagnosis. The study found that statin users achieved complete hematological response (CHR) significantly faster than nonusers (median time: 8 vs 18 months; hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.4-3.1; P = .0003). Among patients treated with pegylated interferon-alfa2 (IFN-α2), the CHR rate was 97% in statin users vs 83% in nonusers (HR, 2.5; 95% CI, 1.5-3.9; P = .0004), and a higher proportion of statin users sustained CHR throughout follow-up. Additionally, IFN-treated statin users received a significantly lower mean dose of IFN-α2. A dose-response relationship was observed, with higher statin intensity associated with an increase of CHR. Furthermore, statin use was significantly associated with achieving a partial molecular response among IFN-α2-treated patients (HR, 2.6; 95% CI, 1.1-6.0; P = .029). No significant association was observed in hydroxyurea (HU)-treated patients. These findings suggest that statins may enhance the efficacy of IFN-α2 in patients with MPN, while their benefit in HU-treated patients remains unclear. Prospective studies are warranted to further explore the therapeutic potential of statins in MPNs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Davidsen ID, Larsen MK, Löffler L, et al. Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms. Blood Adv. 2025. PMID: 40966426. doi:10.1182/bloodadvances.2025017016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。